LGL Group (LGL) Projected to Post Quarterly Earnings on Monday

LGL Group (NYSEAMERICAN:LGL) is projected to release its Q4 2025 results after the market closes on Monday, March 30th. Analysts expect LGL Group to post earnings of $0.0651 per share and revenue of $9.10 million for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, April 3, 2026 at 4:00 PM ET.

LGL Group Trading Down 1.0%

NYSEAMERICAN:LGL opened at $7.19 on Friday. The firm has a fifty day simple moving average of $7.12 and a 200 day simple moving average of $6.48. LGL Group has a 1-year low of $5.45 and a 1-year high of $9.74. The stock has a market capitalization of $46.95 million, a PE ratio of 42.30 and a beta of 0.31.

Insider Activity

In other news, major shareholder Mario J. Gabelli bought 95,387 shares of the business’s stock in a transaction that occurred on Tuesday, December 30th. The stock was acquired at an average cost of $4.75 per share, for a total transaction of $453,088.25. Following the purchase, the insider owned 572,324 shares of the company’s stock, valued at approximately $2,718,539. This trade represents a 20.00% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 18.90% of the company’s stock.

Hedge Funds Weigh In On LGL Group

An institutional investor recently bought a new position in LGL Group stock. Citadel Advisors LLC acquired a new stake in LGL Group, Inc. (The) (NYSEAMERICAN:LGL) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 13,515 shares of the industrial products company’s stock, valued at approximately $90,000. Citadel Advisors LLC owned 0.25% of LGL Group as of its most recent SEC filing. 30.28% of the stock is owned by hedge funds and other institutional investors.

About LGL Group

LGL Group Inc is a United States–based company specializing in the development and commercialization of digital pathology and molecular imaging systems for research and clinical laboratories. The company’s core focus lies in enabling high-resolution visualization and quantitative analysis of tissue samples, helping scientists and pathologists accelerate biomarker discovery and diagnostic workflows. LGL Group’s platform combines advanced optics, automated slide scanning and image analysis software to deliver end-to-end solutions tailored to oncology, immunology and neuroscience research.

The company’s flagship offerings include whole-slide scanners capable of rapid, high-throughput scanning at resolutions suited for detailed morphometric and fluorescence studies.